Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCARF-1
2025-520550-11-00Phase 2Authorised
- Sponsor
- Karolinska Institutet
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eplerenone in heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD), sponsored by Karolinska Institutet. Planned start Aug 2025; status: authorised.
02
Drugs
eplerenone
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2025-520550-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520550-11-00.